NexgenRxNEGXF 40 EBITDA Margin % is 28.88% as of Mar. 2026, which is 173% above its 10-year median of 10.56. GuruFocus rates NEGXF with a GF Score™ of 40/100 and a GF Value™ of $0.22 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 664 Healthcare Providers & Services companies, NexgenRx ranks better than 75.9% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. NexgenRx's EBITDA for the
three
months ended in Mar. 2026 was $1.05 Mil. NexgenRx's Revenue for the
three
months ended in Mar. 2026 was $3.64 Mil. Therefore, NexgenRx's EBITDA margin for the quarter that ended in Mar. 2026 was 28.88%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
NexgenRx EBITDA Margin % Related Terms
NexgenRx EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for NexgenRx's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NEGXF vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, NexgenRx's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NexgenRx EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where NexgenRx's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexgenRx (NEGXF) has a EBITDA Margin % of 28.88% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NexgenRx and its competitors. This is 173% above median its historical median of 10.56. According to the industry distribution chart, NexgenRx ranks #160 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 24.1%.
Is NexgenRx's EBITDA Margin % too high?
NexgenRx's current EBITDA Margin % of 28.88% is 173% above median its 10-year median of 10.56. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. NexgenRx's value of 28.88% is 182.9% above this industry median. Based on the distribution chart, NexgenRx ranks #160 out of 664 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, NexgenRx has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #160 out of 664 companies for EBITDA Margin %. This places NexgenRx in the top 24% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. NexgenRx's value of 28.88% is 182.9% above this benchmark. While the company's 10-year median is 10.56 vs. the industry median of 10.21, NexgenRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NexgenRx's current EBITDA Margin % of 28.88% is 182.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NexgenRx and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexgenRx's current EBITDA Margin % is 28.88%, which is 173% above median its own 10-year median of 10.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.22, compared to a current price of $0.33 — trading 47.7% above its estimated fair value. The current EBITDA Margin % is 28.88%, which is 173% above median its 10-year median of 10.56 and 182.9% above the Healthcare Providers & Services industry median of 10.21. NexgenRx's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For NexgenRx (NEGXF), the current EBITDA Margin % is 28.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (NEGXF) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued.
The current stock price of $0.33 is trading 47.7% above its estimated GF Value™ of $0.22.
GuruFocus considers NexgenRx to be Significantly Overvalued.
Key valuation signals for NEGXF:
EBITDA Margin %: 28.88% (173% above median its 10-year median of 10.56)
GF Value™: $0.22 vs. price of $0.33 (47.7% above fair value)
Industry Position: 182.9% above the Healthcare Providers & Services median (#160 of 664)
No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
40GF Score
Get the complete analysis for NEGXF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEGXF has been successfully added to your 
